Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 1/2013

01-02-2013 | Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

Update on the Angiotensin AT2 Receptor

Authors: Claudia A. McCarthy, Robert E. Widdop, Kate M. Denton, Emma S. Jones

Published in: Current Hypertension Reports | Issue 1/2013

Login to get access

Abstract

It is quite well established that activation of the AT2 receptor (AT2R) provides a counter-regulatory role to AT1R overactivity, particularly during pathological conditions. Indeed, a potential therapeutic role for the AT2R is currently being promulgated with the introduction of novel AT2R ligands such as compound 21 (C21). In this brief review, we will focus on recent evidence to suggest that AT2R exhibits promising organ protection in the context of the heart, kidney and brain, with inflammation and gender influencing outcome. However, this field is not without controversy since the ‘flagship’ ligand C21 has also come under scrutiny, although it is safe to say there is much evidence to support a potentially important role of AT2R in a number of cardiovascular diseases. This report updates recent data in this field.
Literature
1.
Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12:70–88.PubMedCrossRef
2.
Widdop RE, Jones ES, Hannan RE, et al. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140:809–24.PubMedCrossRef
3.
Henrion D, Kubis N, Levy BI. Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension. 2001;38:1150–7.PubMedCrossRef
4.
Wharton J, Morgan K, Rutherford RA, et al. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. J Pharmacol Exp Ther. 1998;284:323–36.PubMed
5.
Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182–91.PubMedCrossRef
6.
Jones ES, Vinh A, McCarthy CA, et al. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292–316.PubMedCrossRef
7.
Hein L, Meinel L, Pratt RE, et al. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol. 1997;11:1266–77.PubMedCrossRef
8.
Widdop RE, Matrougui K, Levy BI, et al. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension. 2002;40:516–20.PubMedCrossRef
9.
Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651–7.PubMedCrossRef
10.
Porrello E, Delbridge L, Thomas W. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci. 2009;14:958–72.PubMedCrossRef
11.
Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should they be applied? Expert Opin Investig Drugs. 2012;21:501–13.PubMedCrossRef
12.
Whitebread S, Mele M, Kamber B, et al. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989;163:284–91.PubMedCrossRef
13.
Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995–6008.PubMedCrossRef
14.
Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523–32.PubMedCrossRef
15.
•• Rompe F, Artuc M, Hallberg A, et al. Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor {kappa}B. Hypertension. 2010;109:147843. The first report that identified mechanisms linking AT 2 receptor stimulation with antiinflammatory effects.
16.
Li XC, Widdop RE. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol. 2004;142:821–30.PubMedCrossRef
17.
Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension. 1999;34:1112–6.PubMedCrossRef
18.
•• Bosnyak S, Welungoda IK, Hallberg A, et al. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 2010;159:709–16. Comprehensive dose-ranging study of the in vitro and in vivo vascular effects of Compound 21.PubMedCrossRef
19.
• Verdonk K, Durik M, Abd-Alla N, et al. Compound 21 Induces Vasorelaxation via an Endothelium- and Angiotensin II Type 2 Receptor-Independent Mechanism / Novelty and Significance. Hypertension. 2012;60:722–9. A controversial study that reported off-target effects of the AT 2 receptor agonist Compound 21, albeit at concentrations up to 10,000-fold higher than its affinity at AT 2 receptors.PubMedCrossRef
20.
Moltzer E, Verkuil AV, van Veghel R, et al. Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation. Hypertension. 2010;55:516–22.PubMedCrossRef
21.
Henrion D. Why do we need a selective angiotensin II type 2 receptor agonist? Hypertension. 2012;60:616–7.PubMedCrossRef
22.
Regoli D, Park WK, Rioux F. Pharmacology of angiotensin. Pharmacol Rev. 1974;26:69–123.PubMed
23.
de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415–72.PubMed
24.
•• Bosnyak S, Jones ES, Christopoulos A, et al. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci. 2011;121:297–303. First study to directly compare a range of Ang peptides in the same study to determine AT 2 :AT 1 receptor selectivity.PubMed
25.
Padia SH, Kemp BA, Howell NL, et al. Conversion of Renal Angiotensin II to Angiotensin III Is Critical for AT2 Receptor Mediated Natriuresis In Rats. Hypertension. 2008;51:460–5.PubMedCrossRef
26.
Padia SH, Kemp BA, Howell NL, et al. Intrarenal Aminopeptidase N Inhibition Augments Natriuretic Responses to Angiotensin III in Angiotensin Type 1 Receptor-Blocked Rats. Hypertension. 2007;49:625–30.PubMedCrossRef
27.
Padia SH, Howell NL, Siragy HM, et al. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension. 2006;47:537–44.PubMedCrossRef
28.
Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1–7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension. 2005;45:960–6.PubMedCrossRef
29.
Vinh A, Widdop RE, Drummond GR, et al. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res. 2008;77:178–87.PubMedCrossRef
30.
• Bosnyak S, Widdop RE, Denton KM, et al. Differential mechanisms of Ang (1–7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. Int J Hypertens. 2012;2012:192567. Striking difference in the vascular phenotype of Ang (1–7) given acutely to either young-adult or aged conscious rats.PubMed
31.
Rosenstrom U, Skold C, Lindeberg G, et al. A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4–5 of angiotensin II. J Med Chem. 2004;47:859–70.PubMedCrossRef
32.
Johannesson P, Erdelyi M, Lindeberg G, et al. AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics. J Med Chem. 2004;47:6009–19.PubMedCrossRef
33.
•• Murugaiah AM, Wu X, Wallinder C, et al. From the first selective non-peptide AT(2) receptor agonist to structurally related antagonists. J Med Chem. 2012;55:2265–78. A recent report of the development of a nonpeptide AT 2 receptor antagonist by minor substitutions to the structure of Compound 21.PubMedCrossRef
34.
•• Jones ES, Del Borgo MP, Kirsch JF, et al. A Single beta-Amino Acid Substitution to Angiotensin II Confers AT(2) Receptor Selectivity and Vascular Function. Hypertension. 2011;57:570–6. Describes how a simple beta-amino acid substitution into the Ang II molecule dramatically alters AT 2 :AT 1 receptor selectivity and function.PubMedCrossRef
35.
Ocaranza MP, Lavandero S, Jalil JE, et al. Angiotensin-(1–9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens. 2010;28:1054–64.PubMedCrossRef
36.
Flores-Munoz M, Smith NJ, Haggerty C, et al. Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol. 2011;589:939–51.PubMedCrossRef
37.
• Flores-Munoz M, Work LM, Douglas K, et al. Angiotensin-(1–9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension. 2012;59:300–7. Antifibrotic effect ascribed to chronic infusion of Ang (1–9) acting at AT 2 receptors, although a contribution by other metabolized Ang peptides and mechanisms needs to be fully ruled out.PubMedCrossRef
38.
Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res. 2000;87:E1–9.PubMedCrossRef
39.
Padia SH, Kemp BA, Howell NL, et al. Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis. Hypertension. 2012;59:437–45.PubMedCrossRef
40.
Salomone LJ, Howell NL, McGrath HE, et al. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension. 2007;49:155–61.PubMedCrossRef
41.
•• Kemp BA, Bell JF, Rottkamp DM, et al. Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension. 2012;60:387–95. Current paper from a series of publications that shows Ang III, but not Ang II or Ang (1–7), causes AT2 receptor mediated natriuresis.PubMedCrossRef
42.
Brown RD, Hilliard LM, Head GA, et al. Sex Differences in the Pressor and Tubuloglomerular Feedback Response to Angiotensin II. Hypertension. 2012;59:129–35.PubMedCrossRef
43.
Sampson AK, Moritz KM, Jones ES, et al. Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension. 2008;52:666–71.PubMedCrossRef
44.
•• Hilliard LM, Nematbakhsh M, Kett MM, et al. Gender Differences in Pressure-Natriuresis and Renal Autoregulation Role of the Angiotensin Type 2 Receptor. Hypertension. 2011;57:275–82. A study demonstrating the greater functional role of AT 2 receptors in renal vasculature in female, as compared to male, rats.PubMedCrossRef
45.
•• Hilliard LM, Jones ES, Steckelings UM, et al. Sex-Specific Influence of Angiotensin Type 2 Receptor Stimulation on Renal Function. Hypertension. 2012;59:409–14. First report showing enhanced AT 2 receptor-mediated renal vasodilator response to Compound 21 in female, as compared to male, rats.PubMedCrossRef
46.
•• Rehman A, Leibowitz A, Yamamoto N, et al. Angiotensin Type 2 Receptor Agonist Compound 21 Reduces Vascular Injury and Myocardial Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats. Hypertension. 2012;59:291–9. One of the first studies to show cardiac antifibrotic effects following chronic treatment with Compound 21, although its potential inhibition by the AT 2 receptor antagonist PD123319 was not examined.PubMedCrossRef
47.
•• Paulis L, Becker STR, Lucht K, et al. Direct Angiotensin II Type 2 Receptor Stimulation in N-Nitro-l-Arginine-Methyl Ester- Induced Hypertension. Hypertension. 2012;59:485–92. One of the first studies to show vessel remodeling following chronic treatment with Compound 21, although its potential inhibition by the AT 2 receptor antagonist PD123319 was not examined.PubMedCrossRef
48.
• Matavelli LC, Huang J, Siragy HM. Angiotensin AT2 Receptor Stimulation Inhibits Early Renal Inflammation in Renovascular Hypertension. Hypertension. 2011;57:308–13. One of the first studies to show anti-inflammatory effects of Compound 21 in the kidney after short-term treatment with Compound 21.PubMedCrossRef
49.
Gelosa P, Pignieri A, Fändriks L, et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444–51.PubMedCrossRef
50.
Foulquier S, Steckelings UM, Unger T. Impact of the AT(2) receptor agonist C21 on blood pressure and beyond. Curr Hypertens Rep. 2012;14:403–9.PubMedCrossRef
51.
Jehle AB, Xu Y, Dimaria JM, et al. A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice. J Cardiovasc Pharmacol. 2012;59:363–8.PubMedCrossRef
52.
McCarthy CA, Vinh A, Callaway JK, et al. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke. 2009;40:1482–9.PubMedCrossRef
53.
•• McCarthy CA, Vinh A, Broughton BR, et al. Angiotensin II Type 2 Receptor Stimulation Initiated After Stroke Causes Neuroprotection in Conscious Rats. Hypertension. 2012, Oct 22 [Epub ahead of print]. Proof-of-principle report showing that CGP42112, given centrally 6 hours after stroke in conscious spontaneously hypertensive rats, still evoked neuroprotection.
54.
•• Lee S, Brait V, Arumugam T, et al. Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Exp Transl Stroke Med. 2012, 4: Aug 24 [Epub ahead of print]. Proof-of-principle report showing that CGP42112, given peripherally at the time of ischaemia/reperfusion in anaesthetised mice, evoked neuroprotection.
55.
Shraim N, Mertens B, Clinckers R, et al. Microbore liquid chromatography with UV detection to study the in vivo passage of compound 21, a non-peptidergic AT2 receptor agonist, to the striatum in rats. J Neurosci Methods. 2011;202:137–42.PubMedCrossRef
56.
• Mecca AP, Regenhardt RW, O'Connor TE, et al. Cerebroprotection by angiotensin-(1–7) in endothelin-1-induced ischaemic stroke. Exp Physiol. 2011;96:1084–96. First report showing that Ang (1–7) can also evoke neuroprotective effects.PubMed
57.
Tota S, Hanif K, Kamat PK, et al. Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function. Psychopharmacology (Berl). 2012;222:185–202.CrossRef
58.
•• Jing F, Mogi M, Sakata A, et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab. 2012;32:248–55. First report on the improved cognitive effects of Compound 21.PubMedCrossRef
59.
• Horiuchi M, Iwanami J, Mogi M. Regulation of angiotensin II receptors beyond the classical pathway. Clin Sci. 2012;123:193–203. An excellent recent review summarising a number of aspects of nonclassical Ang signaling that are not covered in the current update.PubMedCrossRef
Metadata
Title
Update on the Angiotensin AT2 Receptor
Authors
Claudia A. McCarthy
Robert E. Widdop
Kate M. Denton
Emma S. Jones
Publication date
01-02-2013
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 1/2013
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-012-0321-4

Other articles of this Issue 1/2013

Current Hypertension Reports 1/2013 Go to the issue

Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

Treatment of Arterial Remodeling in Essential Hypertension

Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

Pathophysiology of Hypertension in the Absence of Nitric Oxide/Cyclic GMP Signaling

Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

The “His and Hers” of the Renin-Angiotensin System

Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

Opportunities for Targeting the Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Receptor Pathway in Hypertension

Invited Commentary

Mild Hypertension: To Treat or Not to Treat?

Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

The Renin Angiotensin Aldosterone System and Insulin Resistance in Humans
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits